Circulating miR-483-3p and miR-21 is highly expressed in plasma of pancreatic cancer

International Journal of Oncology

Volumn 46, Issue 2, 2015, Pages 539-547

  Abue, Makoto ^a   Yokoyama, Misa ^a   Shibuya, Rie ^a   Tamai, Keiichi ^a   Yamaguchi, Kazunori ^a   Sato, Ikuro ^b   Tanaka, Nobuyuki ^a   Hamada, Shin ^c   Shimosegawa, Tooru ^c   Sugamura, Kazuo ^a   Satoh, Kennichi ^a  

^a MIYAGI CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b Miyagi Cancer Center   (Japan)

^c TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Biomarker; MiR 21; MiR 483 3p; Pancreatic cancer; Plasma

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; MICRORNA 21; MICRORNA 483 3P; UNCLASSIFIED DRUG; MIRN21 MICRORNA, HUMAN; MIRN483 MICRORNA, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; ADENOCARCINOMA; BIOSYNTHESIS; BLOOD; DIFFERENTIAL DIAGNOSIS; GENE EXPRESSION REGULATION; GENETICS; INTRADUCTAL CARCINOMA; LYMPH NODE; MIDDLE AGED; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; VERY ELDERLY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CARCINOMA, PANCREATIC DUCTAL; DIAGNOSIS, DIFFERENTIAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPH NODES; MALE; MICRORNAS; MIDDLE AGED; PANCREATIC NEOPLASMS;

EID: 84918548307     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2743     Document Type: Article

References (53)

1. Hirata K, Egawa S, Kimura Y, et al: Current status of surgery for pancreatic cancer. Dig Surg 24: 137-147, 2007.
2. Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin 64: 9-29, 2014.
3. Vincent A, Herman J, Schulick R, Hruban RH and Goggins M: Pancreatic cancer. Lancet 378: 607-620, 2011.
4. Satake K, Kanazawa G, Kho I, Chung YS and Umeyama K: A clinical evaluation of carbohydrate antigen 19-9 and carcinoembryonic antigen in patients with pancreatic carcinoma. J Surg Oncol 29: 15-21, 1985.
5. Lee RC, Feinbaum RL and Ambros V: The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75: 843-854, 1993.
6. Dillhoff M, Liu J, Frankel W, Croce C and Bloomston M: MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival. J Gastrointest Surg 12: 2171-2176, 2008.
7. Bloomston M, Frankel WL, Petrocca F, et al: MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 297: 1901-1908, 2007.
8. Habbe N, Koorstra JB, Mendell JT, et al: MicroRNA miR-155 is a biomarker of early pancreatic neoplasia. Cancer Biol Ther 8: 340-346, 2009.
9. Ryu JK, Hong SM, Karikari CA, Hruban RH, Goggins MG and Maitra A: Aberrant microRNA-155 expression is an early event in the multistep progression of pancreatic adenocarcinoma. Pancreatology 10: 66-73, 2010.
10. Li Y, Vandenboom TG II, Wang Z, Kong D, Ali S, Philip PA and Sarkar FH: miR-146a suppresses invasion of pancreatic cancer cells. Cancer Res 70: 1486-1495, 2010.
11. Z hang Y, Li M, Wang H, Fisher WE, Lin PH, Yao Q and Chen C: Profiling of 95 microRNAs in pancreatic cancer cell lines and surgical specimens by real-time PCR analysis. World J Surg 33: 698-709, 2009.
12. Yu J, Li A, Hong SM, Hruban RH and Goggins M: MicroRNA alterations of pancreatic intraepithelial neoplasias. Clin Cancer Res 18: 981-992, 2012.
13. K ent OA, Mullendore M, Wentzel EA, et al: A resource for analysis of microRNA expression and function in pancreatic ductal adenocarcinoma cells. Cancer Biol Ther 8: 2013-2024, 2009.
14. Li A, Omura N, Hong SM, et al: Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels. Cancer Res 70: 5226-5237, 2010.
15. Yu J, Ohuchida K, Mizumoto K, et al: MicroRNA, hsa-miR-200c, is an independent prognostic factor in pancreatic cancer and its upregulation inhibits pancreatic cancer invasion but increases cell proliferation. Mol Cancer 9: 169, 2010.
16. Lee EJ, Gusev Y, Jiang J, et al: Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer 120: 1046-1054, 2007.
17. Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-866, 2006.
18. Chen X, Ba Y, Ma L, et al: Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18: 997-1006, 2008.
19. Filipowicz W, Bhattacharyya SN and Sonenberg N: Mechanisms of posttranscriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 9: 102-114, 2008.
20. Mitchell PS, Parkin RK, Kroh EM, et al: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105: 10513-10518, 2008.
21. Hasselmann DO, Rappl G, Tilgen W and Reinhold U: Extracellular tyrosinase mRNA within apoptotic bodies is protected from degradation in human serum. Clin Chem 47: 1488-1489, 2001.
22. Cocucci E, Racchetti G and Meldolesi J: Shedding microvesicles: artefacts no more. Trends Cell Biol 19: 43-51, 2009.
23. K osaka N, Iguchi H, Yoshioka Y, Takeshita F, Matsuki Y and Ochiya T: Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem 285: 17442-17452, 2010.
24. Arroyo JD, Chevillet JR, Kroh EM, et al: Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci USA 108: 5003-5008, 2011.
25. Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD and Remaley AT: MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 13: 423-433, 2011.
26. Wang J, Chen J, Chang P, et al: MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel bloodbased biomarkers of disease. Cancer Prev Res (Phila) 2: 807-813, 2009.
27. Morimura R, Komatsu S, Ichikawa D, et al: Novel diagnostic value of circulating miR-18a in plasma of patients with pancreatic cancer. Br J Cancer 105: 1733-1740, 2011.
28. Ho AS, Huang X, Cao H, Christman-Skieller C, Bennewith K, Le QT and Koong AC: Circulating miR-210 as a novel hypoxia marker in pancreatic cancer. Transl Oncol 3: 109-113, 2010.
29. K awaguchi T, Komatsu S, Ichikawa D, et al: Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer. Br J Cancer 108: 361-369, 2013.
30. Moriyama T, Ohuchida K, Mizumoto K, et al: MicroRNA-21 modulates biological functions of pancreatic cancer cells including theirproliferation, invasion, and chemoresistance. Mol Cancer Ther 8: 1067-1074, 2009.
31. Giovannetti E, Funel N, Peters GJ, et al: MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res 70: 4528-4538, 2010.
32. Hwang JH, Voortman J, Giovannetti E, et al: Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS One 5: e10630, 2010.
33. K adera BE, Li L, Toste PA, Wu N, Adams C, Dawson DW and Donahue TR: MicroRNA-21 in pancreatic ductal adenocarcinoma tumor-associated fibroblasts promotes metastasis. PLoS One 8: e71978, 2013.
34. Liu R, Chen X, Du Y, et al: Serum miRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. Clin Chem 58: 610-618, 2012.
35. Ali S, Almhanna K, Chen W, Philip PA and Sarkar FH: Differentially expressed miRNAs in the plasma may provide a molecular signature for aggressive pancreatic cancer. Am J Transl Res 28: 28-47, 2010.
36. Liu J, Gao J, Du Y, et al: Combination of plasma microRNAs with serum CA19-9 for early detection of pancreatic cancer. Int J Cancer 131: 683-691, 2012.
37. K ong X, Du Y, Wang G, et al: Detection of differentially expressed microRNAs in serum of pancreatic ductal adenocarcinoma patients: miR-196a could be a potential marker for poor prognosis. Dig Dis Sci 56: 602-609, 2011.
38. Hamada S, Satoh K, Fujibuchi W, et al: MiR-126 acts as a tumor suppressor in pancreatic cancer cells via the regulation of ADAM9. Mol Cancer Res 10: 3-10, 2012.
39. Hamada S, Satoh K, Miura S, et al: MiR-197 induces epithelialmesenchymal transition in pancreatic cancer cells by targeting p120 catenin. J Cell Physiol 228: 1255-1263, 2013.
40. Veronese, A, Lupini L, Consiqlio J, et al: Oncogenic role of miR-483-3p at the IGF2/483 locus. Cancer Res 70: 3140-3149, 2010.
41. Guled M, Lahti L, Lindholm PM, Salmenkivi K, Bagwan I, Nicholson AG and Knuutila S: CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma- A miRNA microarray analysis. Genes Chromosomes Cancer 48: 615-623, 2009.
42. Hao J, Zhang S, Zhou Y, Hu X and Shao C: MicroRNA 483-3p suppresses the expression of DPC4/Smad4 in pancreatic cancer. FEBS Lett 585: 207-213, 2011.
43. Sobin LH, Gospodarowicz MK and Wittekind C (eds): TNM Cassification of Malignant Tumours. 7th edition. Wiley-Blackwell, New York, NY, 2009.
44. Schmittgen TD and Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3: 1101-1108, 2008.
45. Liang Y, Ridzon D, Wong L and Chen C: Characterization of microRNA expression profiles in normal human tissues. BMC Genomics 8: 166, 2007.
46. Wilentz RE, Iacobuzio-Donahue CA, Argani P, et al: Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res 60: 2002-2006, 2000.
47. Biankin AV1, Biankin SA, Kench JG, et al: Aberrant p16 (INK4A) and DPC4/Smad4 expression in intraductal papillary mucinous tumours of the pancreas is associated with invasive ductal adenocarcinoma. Gut 50: 861-868, 2002.
48. Yamaguchi K1, Ohuchida J, Ohtsuka T, Nakano K and Tanaka M: Intraductal papillary-mucinous tumor of the pancreas concomitant with ductal carcinoma of the pancreas. Pancreatology 2: 484-490, 2002.
49. Uehara H, Nakaizumi A, Ishikawa O, et al: Development of ductal carcinoma of the pancreas during follow-up of branch duct intraductal papillary mucinous neoplasm of the pancreas. Gut 57: 1561-1565, 2008.
50. Tanno S, Nakano Y, Koizumi K, et al: Pancreatic ductal adenocarcinomas in long-term follow-up patients with branch duct intraductal papillary mucinous neoplasms. Pancreas 39: 36-40, 2010.
51. Ingkakul T1, Sadakari Y, Ienaga J, Satoh N, Takahata S and Tanaka M: Predictors of the presence of concomitant invasive ductal carcinoma in intraductal papillary mucinous neoplasm of the pancreas. Ann Surg 25: 70-75, 2010.
52. K anno A, Satoh K, Hirota M, et al: Prediction of invasive carcinoma in branch type intraductal pappilary mucinous neoplasms of the pancreas. J Gastroenterol 45: 952-959, 2010.
53. Li A1, Yu J, Kim H, Wolfgang CL, Canto MI, Hruban RH and Goggins M: MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls. Clin Cancer Res 19: 3600-3610, 2013.